Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Curie-Cancer Trebles Early Phase Clinical Research Studies with Industry Partners

Published: Tuesday, March 26, 2013
Last Updated: Tuesday, March 26, 2013
Bookmark and Share
Ten early stage clinical studies (phase I) were conducted in 2012, trebling since 2010 and continuing to grow in 2013.

Curie-Cancer has announced a strong increase in the number of early stage clinical trials (phase I) from three in 2010 to ten in 2012. The studies are being conducted with industry partners.

The rise in the number of studies is a direct result of the changes in strategic direction put in place by professor Pierre Teillac, director of the Institut Curie Hospital Group and the recent launch of the Clinical Research Department, headed by Veronique Dieras, in response to the needs of industry partners.

These studies aim to evaluate a compound’s safety and pharmacokinetics (absorption rate, elimination rate, maximum blood concentration, etc.) in patients to establish the subsequent dosage of the drug.

The studies also research the first signs of efficacy. These studies are becoming increasingly crucial to the pharmaceutical companies, who seek experienced investigation that is reliable, efficient and reduces turnaround.

“The 2012 increase in early stage clinical trials for Curie-Cancer is rather remarkable. Due to contracts signed at the start of 2013, we expect the number to continue to climb significantly,” said Christophe Le Tourneau, the oncologist responsible for the Institut Curie’s early stage clinical studies.

Tourneau continued, “We have many diverse industry partners working on studies of different types of cancer. They range from French SMEs to international groups.”

Dr Patricia Tresca, who has extensive experience within the pharmaceutical industry, now leads the body in charge of managing clinical trials for Curie-Cancer.

She was recruited for her working knowledge of the industry partner types Curie-Cancer targets. Curie-cancer has been tasked with improving responsiveness and inclusion rates in patients.

It will help industry partners to obtain the reports they need in time to make their decisions faster. Industry partners will also be able to request the necessary authorizations from the monitoring authorities in order to proceed to the next development stages.

Curie-Cancer’s main advantage is achieving the close collaboration between research doctors, who are conducting the trials and the researchers in charge of translational and/or fundamental research.

In the age of genomics and proteomics, preliminary studies are often best conducted at the cutting edge of academic research. As researchers are involved in conducting the preclinical studies, they are in a position to best interpret the results.

They can therefore make the right decisions quickly. An increasing number of the products studied in “first in man“ trials at the Institut Curie have also been studied previously in preclinical studies commissioned by industry partners with different research laboratories on campus.

Another advantage is Curie-Cancer’s ability to conduct early stage clinical studies for industry partners accustomed to commissioning preclinical studies with them.

They know that the partnership will bring benefits from conducting further clinical studies of their products in development.

The opportunity for researchers to participate in these early stage studies, upon which the future of many products is decided, is very interesting. It allows them to link concepts derived in a laboratory, through in vitro or animal test results, to the first observations in patients.

“Clinical research has meaning only if it makes innovative products available to patients. Allowing early stage access to these products in development within pharmaceutical laboratories is an additional opportunity for those whose commercially available products are not efficient enough,” said Damien Salauze, director of Curie-Cancer.

Salauze continued, “We are pleased that the expertise and knowledge that Curie-Cancer brings to our industry partners can be combined with added hope for patients.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Curie-Cancer and Strand Launch Curie Image Database
A breakthrough image management platform for scientists.
Wednesday, December 18, 2013
Curie-Cancer and Meiogenix Sign Two Partnership Agreements
Curie-Cancer and Meiogenix will develop the SpiX technology in yeast and in mice to unlock unexplored genetic diversity.
Tuesday, November 19, 2013
Curie-Cancer and Harmonic Pharma Sign a Partnership Agreement
Under this multi-year research collaboration, Curie-Cancer will give Harmonic Pharma access to its extensive collection of patient-derived xenografts representative of human tumors.
Tuesday, November 06, 2012
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos